Policy corpus

The coverage policies we hold

One row per policy: the contractor that issued it, the effective date CMS published, how many distinct versions of its text we have captured, and the CMS document. Every row links to its source. Nothing here is behind a login. The dated change feed is a different view of the same records.

1,097 local coverage determinations · page 11 of 11

PolicyTitleContractorEffectiveVersions heldSource
DL33930Proposed LCD DL33930: Facet Joint Interventions for Pain ManagementFirst Coast1cms.gov ↗
DL34356Proposed LCD DL34356: Erythropoiesis Stimulating Agents (ESA)CGS Administrators1cms.gov ↗
DL34410Proposed LCD DL34410: B-type Natriuretic Peptide (BNP) TestingPalmetto GBA1cms.gov ↗
DL34892Proposed LCD DL34892: Facet Joint Interventions for Pain ManagementNovitas1cms.gov ↗
DL35000Proposed LCD DL35000: Molecular Pathology ProceduresNational Government Services1cms.gov ↗
DL35010Proposed LCD DL35010: Trigger Point InjectionsNovitas1cms.gov ↗
DL35170Proposed LCD DL35170: Botulinum Toxin InjectionsNoridian1cms.gov ↗
DL35172Proposed LCD DL35172: Botulinum Toxin InjectionsNoridian1cms.gov ↗
DL36351Proposed LCD DL36351: Lab: Special Histochemical Stains and Immunohistochemical StainsNoridian1cms.gov ↗
DL36353Proposed LCD DL36353: Lab: Special Histochemical Stains and Immunohistochemical StainsNoridian1cms.gov ↗
DL36408Proposed LCD DL36408: Allergen Immunotherapy (AIT) with Subcutaneous Immunotherapy (SCIT)WPS1cms.gov ↗
DL37421Proposed LCD DL37421: Magnetic Resonance Image Guided High Intensity Focused Ultrasound (MRgFUS) for TremorNational Government Services1cms.gov ↗
DL38367Proposed LCD DL38367: Fluid Jet System Treatment for LUTS/BPHNational Government Services1cms.gov ↗
DL38378Proposed LCD DL38378: Fluid Jet System in the Treatment of Benign Prostatic Hyperplasia (BPH)CGS Administrators1cms.gov ↗
DL38549Proposed LCD DL38549: Transurethral Waterjet Ablation of the ProstatePalmetto GBA1cms.gov ↗
DL38571Proposed LCD DL38571: Colon Capsule Endoscopy (CCE)National Government Services1cms.gov ↗
DL38682Proposed LCD DL38682: Transurethral Waterjet Ablation of the ProstateWPS1cms.gov ↗
DL38705Proposed LCD DL38705: Transurethral Waterjet Ablation of the ProstateNoridian1cms.gov ↗
DL38707Proposed LCD DL38707: Transurethral Waterjet Ablation of the ProstateNoridian1cms.gov ↗
DL39297Proposed LCD DL39297: Off-label Use of Rituximab and Rituximab BiosimilarsNational Government Services1cms.gov ↗
DL39314Proposed LCD DL39314: Off-Label Use of Intravenous Immune Globulin (IVIG)National Government Services1cms.gov ↗
DL39832Proposed LCD DL39832: Botulinum Toxin InjectionsNational Government Services1cms.gov ↗
DL39836Proposed LCD DL39836: Botulinum Toxin InjectionsPalmetto GBA1cms.gov ↗
DL39857Proposed LCD DL39857: Botulinum Toxin InjectionsCGS Administrators1cms.gov ↗
DL39909Proposed LCD DL39909: Botulinum Toxin InjectionsWPS1cms.gov ↗
DL39923Proposed LCD DL39923: MolDX: Non-Next Generation Sequencing Tests for the Diagnosis of BCR-ABL Negative Myeloproliferative NeoplasmsNoridiancms.gov ↗
DL39927Proposed LCD DL39927: MolDX: Non-Next Generation Sequencing Tests for the Diagnosis of BCR-ABL Negative Myeloproliferative NeoplasmsNoridiancms.gov ↗
DL40000Proposed LCD DL40000: MolDX: Non-Next Generation Sequencing Tests for the Diagnosis of BCR-ABL Negative Myeloproliferative NeoplasmsCGS Administratorscms.gov ↗
DL40022Proposed LCD DL40022: MolDX: Non-Next Generation Sequencing Tests for the Diagnosis of BCR-ABL Negative Myeloproliferative NeoplasmsWPScms.gov ↗
DL40048Proposed LCD DL40048: Allergen Immunotherapy (AIT) with Subcutaneous Immunotherapy (SCIT)National Government Servicescms.gov ↗
DL40050Proposed LCD DL40050: Allergen Immunotherapy (AIT) with Subcutaneous Immunotherapy (SCIT)Noridian1cms.gov ↗
DL40052Proposed LCD DL40052: Allergen Immunotherapy (AIT) with Subcutaneous Immunotherapy (SCIT)Noridian1cms.gov ↗
DL40058Proposed LCD DL40058: MolDX: Molecular Testing for Solid Organ Allograft RejectionPalmetto GBA1cms.gov ↗
DL40060Proposed LCD DL40060: MolDX: Molecular Testing for Solid Organ Allograft RejectionNoridian1cms.gov ↗
DL40062Proposed LCD DL40062: MolDX: Molecular Testing for Solid Organ Allograft RejectionNoridian1cms.gov ↗
DL40140Proposed LCD DL40140: MolDX: Molecular Testing for Solid Organ Allograft RejectionCGS Administrators1cms.gov ↗
DL40142Proposed LCD DL40142: MolDX: Biomarker Testing for Risk Stratification in DCISPalmetto GBA1cms.gov ↗
DL40144Proposed LCD DL40144: MolDX: Biomarker Testing for Risk Stratification in DCISNoridian1cms.gov ↗
DL40168Proposed LCD DL40168: Superficial Radiation Therapy (SRT) for the Treatment of Nonmelanoma Skin Cancers (NMSC)National Government Services1cms.gov ↗
DL40176Proposed LCD DL40176: Superficial Radiation Therapy (SRT) for the Treatment of Nonmelanoma Skin Cancers (NMSC)Noridian1cms.gov ↗
DL40179Proposed LCD DL40179: Superficial Radiation Therapy (SRT) for the Treatment of Nonmelanoma Skin Cancers (NMSC)CGS Administrators1cms.gov ↗
DL40187Proposed LCD DL40187: MolDX: Biomarker Testing for Risk Stratification in Metabolic Dysfunction-Associated Steatotic Liver Disease and Metabolic Dysfunction-Associated SteatohepatitisPalmetto GBA1cms.gov ↗
DL40189Proposed LCD DL40189: Superficial Radiation Therapy (SRT) for the Treatment of Nonmelanoma Skin Cancers (NMSC)Palmetto GBA1cms.gov ↗
DL40193Proposed LCD DL40193: Superficial Radiation Therapy (SRT) for the Treatment of Nonmelanoma Skin Cancers (NMSC)WPS1cms.gov ↗
DL40197Proposed LCD DL40197: MolDX: Biomarker Testing for Risk Stratification in Metabolic Dysfunction-Associated Steatotic Liver Disease and Metabolic Dysfunction-Associated SteatohepatitisNoridian1cms.gov ↗
DL40199Proposed LCD DL40199: MolDX: Biomarker Testing for Risk Stratification in Metabolic Dysfunction-Associated Steatotic Liver Disease and Metabolic Dysfunction-Associated SteatohepatitisCGS Administrators1cms.gov ↗
DL40205Proposed LCD DL40205: Irreversible Electroporation for CancerPalmetto GBA1cms.gov ↗
DL40210Proposed LCD DL40210: MolDX: Non-Next Generation Sequencing Targeted Molecular Panel Tests for Predictive Testing in CancerPalmetto GBA1cms.gov ↗
DL40222Proposed LCD DL40222: MolDX: Non-Next Generation Sequencing Targeted Molecular Panel Tests for Predictive Testing in CancerNoridian1cms.gov ↗
DL40224Proposed LCD DL40224: Automated Detection and Quantification of Brain MRIsCGS Administrators1cms.gov ↗
DL40226Proposed LCD DL40226: MolDX: Non-Next Generation Sequencing Targeted Molecular Panel Tests for Predictive Testing in CancerCGS Administrators1cms.gov ↗
DL40228Proposed LCD DL40228: Endovascular Management for Peripheral Arterial Disease of the Upper and Lower ExtremitiesPalmetto GBA1cms.gov ↗
DL40232Proposed LCD DL40232: Total Joint ArthroplastyCGS Administrators1cms.gov ↗
DL40238Proposed LCD DL40238: MolDX: Genetic Testing for Hereditary ThrombophiliaPalmetto GBA1cms.gov ↗
DL40242Proposed LCD DL40242: MolDX: Genetic Testing for Hereditary ThrombophiliaNoridian1cms.gov ↗
DL40244Proposed LCD DL40244: Temporary Nontherapeutic Ambulatory Cardiac Monitoring DevicesCGS Administrators1cms.gov ↗
DL40246Proposed LCD DL40246: MolDX: Biomarker Testing for Risk Stratification in DCISCGS Administrators1cms.gov ↗
DL40249Proposed LCD DL40249: MolDX: Molecular Testing for Solid Organ Allograft RejectionWPS1cms.gov ↗
DL40251Proposed LCD DL40251: MolDX: Biomarker Testing for Risk Stratification in DCISWPS1cms.gov ↗
DL40255Proposed LCD DL40255: Temporary Nontherapeutic Ambulatory Cardiac Monitoring DevicesNoridian1cms.gov ↗
DL40257Proposed LCD DL40257: Temporary Nontherapeutic Ambulatory Cardiac Monitoring DevicesPalmetto GBA1cms.gov ↗
DL40259Proposed LCD DL40259: MolDX: Genetic Testing for Hereditary ThrombophiliaCGS Administrators1cms.gov ↗
DL40261Proposed LCD DL40261: Peripheral Nerve Blocks and Procedures for Chronic PainCGS Administrators1cms.gov ↗
DL40263Proposed LCD DL40263: Peripheral Nerve Blocks and Procedures for Chronic PainPalmetto GBA1cms.gov ↗
DL40265Proposed LCD DL40265: Peripheral Nerve Blocks and Procedures for Chronic PainNoridian1cms.gov ↗
DL40267Proposed LCD DL40267: Peripheral Nerve Blocks and Procedures for Chronic PainNational Government Services1cms.gov ↗
DL40272Proposed LCD DL40272: MolDX: Biomarker Testing for Risk Stratification in Metabolic Dysfunction-Associated Steatotic Liver Disease and Metabolic Dysfunction-Associated SteatohepatitisWPS1cms.gov ↗
DL40274Proposed LCD DL40274: MolDX: Genetic Testing for Hereditary ThrombophiliaWPS1cms.gov ↗
DL40276Proposed LCD DL40276: Non-invasive Arterial Duplex Ultrasound of the Upper and Lower ExtremitiesNovitas1cms.gov ↗
DL40278Proposed LCD DL40278: MolDX: Non-Next Generation Sequencing Targeted Molecular Panel Tests for Predictive Testing in CancerWPS1cms.gov ↗
DL40289Proposed LCD DL40289: Non-invasive Arterial Duplex Ultrasound of the Upper and Lower ExtremitiesFirst Coast1cms.gov ↗
DL40300Proposed LCD DL40300: Peripheral Nerve Blocks and Procedures for Chronic PainWPS1cms.gov ↗
DL40302Proposed LCD DL40302: Thermal Destruction of the Intraosseous Basivertebral Nerve (BVN) for Vertebrogenic Lower Back PainNational Government Services1cms.gov ↗
DL40324Proposed LCD DL40324: Allergy Diagnostic TestingNoridian1cms.gov ↗
DL40326Proposed LCD DL40326: Allergy Diagnostic TestingCGS Administrators1cms.gov ↗
DL40328Proposed LCD DL40328: Allergy Diagnostic TestingPalmetto GBA1cms.gov ↗
DL40330Proposed LCD DL40330: Allergy Diagnostic TestingNational Government Services1cms.gov ↗
DL40332Proposed LCD DL40332: Automated Detection and Quantification of Brain MRIsNational Government Services1cms.gov ↗
DL40334Proposed LCD DL40334: Erythropoiesis Stimulating AgentsNational Government Services1cms.gov ↗
DL40341Proposed LCD DL40341: Allergy Diagnostic TestingWPS1cms.gov ↗
DL40343Proposed LCD DL40343: Computed Tomography Cerebral Perfusion Analysis (CTP)WPS1cms.gov ↗
DL40356Proposed LCD DL40356: Anterior segment intraocular nonbiodegradable drug-eluting systemCGS Administrators1cms.gov ↗
DL40359Proposed LCD DL40359: Anterior Segment Intraocular Nonbiodegradable Drug-eluting SystemNoridian1cms.gov ↗
DL40363Proposed LCD DL40363: Anterior segment intraocular nonbiodegradable drug-eluting systemNational Government Services1cms.gov ↗
DL40367Proposed LCD DL40367: Anterior segment intraocular nonbiodegradable drug-eluting systemPalmetto GBA1cms.gov ↗
DL40378Proposed LCD DL40378: Urine-based Biomarkers in Patients with MicrohematuriaNovitas1cms.gov ↗
DL40380Proposed LCD DL40380: Urine-based Biomarkers in Patients with MicrohematuriaFirst Coast1cms.gov ↗
DL40385Proposed LCD DL40385: Anterior segment intraocular nonbiodegradable drug-eluting systemWPS1cms.gov ↗
DL40407Proposed LCD DL40407: MolDX: Genome-Wide Molecular Methodologies for the Detection of Copy Number Alterations and Structural Variants in Hematologic NeoplasmsPalmetto GBA1cms.gov ↗
DL40411Proposed LCD DL40411: MolDX: Genome-Wide Molecular Methodologies for the Detection of Copy Number Alterations and Structural Variants in Hematologic NeoplasmsNoridian1cms.gov ↗
DL40425Proposed LCD DL40425: MolDX: Next-Generation Sequencing for Hematologic Malignancies and Suspected Hematologic MalignanciesPalmetto GBA1cms.gov ↗
DL40427Proposed LCD DL40427: MolDX: Next-Generation Sequencing for Hematologic Malignancies and Suspected Hematologic MalignanciesNoridian1cms.gov ↗
DL40429Proposed LCD DL40429: MolDX: Transcriptional Biomarkers for Therapeutic Decision-Making in Renal CarcinomaPalmetto GBA1cms.gov ↗
DL40431Proposed LCD DL40431: MolDX: Genome-Wide Molecular Methodologies for the Detection of Copy Number Alterations and Structural Variants in Hematologic NeoplasmsCGS Administrators2cms.gov ↗
DL40433Proposed LCD DL40433: MolDX: Transcriptional Biomarkers for Therapeutic Decision-Making in Renal CarcinomaCGS Administrators2cms.gov ↗
DL40435Proposed LCD DL40435: MolDX: Transcriptional Biomarkers for Therapeutic Decision-Making in Renal CarcinomaNoridian1cms.gov ↗
DL40451Proposed LCD DL40451: MolDX: Next-Generation Sequencing for Hematologic Malignancies and Suspected Hematologic MalignanciesCGS Administrators2cms.gov ↗

“Versions held” counts distinct captured texts of the policy since capture began; a policy captured once has one. A “—” means the count could not be read on this load, not that none are held. How versions are captured and dated is on Methodology.